Show simple item record

dc.contributor.authorAgarwal, Pallavien
dc.contributor.authorJackson, Stephenen
dc.date.accessioned2016-08-22T15:02:30Z
dc.date.available2016-08-22T15:02:30Z
dc.date.issued2016-07-16en
dc.identifier.issn0304-3835
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/257370
dc.description.abstractCancer cells often exhibit altered epigenetic signatures that can misregulate genes involved in processes such as transcription, proliferation, apoptosis and DNA repair. As regulation of chromatin structure is crucial for DNA repair processes, and both DNA repair and epigenetic controls are deregulated in many cancers, we speculated that simultaneously targeting both might provide new opportunities for cancer therapy. Here, we describe a focused screen that profiled small-molecule inhibitors targeting epigenetic regulators in combination with DNA double-strand break (DSB) inducing agents. We identify UNC0638, a catalytic inhibitor of histone lysine N-methyl-transferase G9a, as hypersensitising tumour cells to low doses of DSB-inducing agents without affecting the growth of the non-tumorigenic cells tested. Similar effects are also observed with another, structurally distinct, G9a inhibitor A-366. We also show that small-molecule inhibition of G9a or siRNA-mediated G9a depletion induces tumour cell death under low DNA damage conditions by impairing DSB repair in a p53 independent manner. Furthermore, we establish that G9a promotes DNA non-homologous end-joining in response to DSB-inducing genotoxic stress. This study thus highlights the potential for using G9a inhibitors as anti-cancer therapeutic agents in combination with DSB-inducing chemotherapeutic drugs such as etoposide.
dc.description.sponsorshipResearch in the S.P.J. laboratory is funded by Cancer Research UK Program Grant C6/A18796 and the European Research Council (DDREAM) grant 268536-DDRREAM. Core infrastructure funding was provided by Cancer Research UK Grant C6946/ A14492 and Wellcome Trust Grant WT092096. S.P.J. receives a salary from the University of Cambridge, supplemented by Cancer Research UK. P.A. was financially supported by CRUK grant C6/ A11224 and ERC grant DDREAM.
dc.languageEnglishen
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution 4.0 International*
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectcancer epigeneticsen
dc.subjectchemical probesen
dc.subjectUNC0638en
dc.subjectchemotherapeuticsen
dc.subjectnon-homologous end joiningen
dc.titleG9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 statusen
dc.typeArticle
dc.description.versionThis is the final version of the article. It first appeared from Elsevier via http://dx.doi.org/10.1016/j.canlet.2016.07.009en
prism.endingPage475
prism.publicationDate2016en
prism.publicationNameCancer Lettersen
prism.startingPage467
prism.volume380en
dc.identifier.doi10.17863/CAM.1305
dcterms.dateAccepted2016-07-11en
rioxxterms.versionofrecord10.1016/j.canlet.2016.07.009en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2016-07-16en
dc.contributor.orcidJackson, Stephen [0000-0001-9317-7937]
dc.identifier.eissn1872-7980
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idCancer Research UK (A18796)
pubs.funder-project-idEuropean Research Council (268536)
pubs.funder-project-idWellcome Trust (092096/Z/10/Z)
pubs.funder-project-idCancer Research UK (A14492)
cam.orpheus.successThu Jan 30 12:57:18 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International